Determinants of fibroblast growth factor-23 and parathyroid hormone variability in dialysis patients

American Journal of Nephrology

Volumn 37, Issue 5, 2013, Pages 462-471

  Jia, Ting ^a   Qureshi, Abdul Rashid ^a   Brandenburg, Vincent ^d   Ketteler, Markus ^e   Barany, Peter ^a   Heimburger, Olof ^a   Uhlin, Fredrik ^c   Magnusson, Per ^c   Fernström, Anders ^c   Lindholm, Bengt ^a   Stenvinkel, Peter ^a,b   Larsson, Tobias E ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e KLINIKUM COBURG   (Germany)

Author keywords

Chronic kidney disease; FGF23; Fibroblast growth factor 23; Parathyroid hormone; PTH

Indexed keywords

25 HYDROXYVITAMIN D; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; LIPID; PARATHYROID HORMONE; PHOSPHORUS; PHOSPHATE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN DETERMINATION; VITAMIN BLOOD LEVEL; MIDDLE AGED; PARATHYROID HORMONE BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HEMODIAFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PERITONEAL DIALYSIS; PHOSPHORUS; VITAMIN D;

EID: 84876796232     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000350537     Document Type: Article

References (41)

1. Slatopolsky E, Delmez JA: Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994; 23: 229-236
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009;S1-S130
4. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-S266
5. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770- 779
6. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium . phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31: 607-617
7. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM: Arterial calcification in chronic kidney disease: Key roles for calcium and phosphate. Circ Res 2011; 109: 697-711
8. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: 622-631
9. Larsson TE: The role of FGF-23 in CKDMBD and cardiovascular disease: Friend or foe? Nephrol Dial Transplant 2010; 25: 1376- 1381
10. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M: Fibroblast growth factor-23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
11. Wolf M: Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010; 21: 1427-1435
12. Taylor EN, Rimm EB, Stampfer MJ, Curhan GC: Plasma fibroblast growth factor-23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J 2011; 161: 956-962
13. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick DS, Sarnak MJ, Shlipak MG: Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60: 200-207
14. Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, Larsson TE: Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 20113; 83: 160- 166
15. Gardham C, Stevens PE, Delaney MP, Le- Roux M, Coleman A, Lamb EJ: Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol 2010; 5: 1261-1267
16. Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function: New insights into old concepts. Clin Chem 1992; 38: 1933-1953
17. Al-Aly Z: Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients: The need for randomized trials. Kidney Int 2007; 72: 909-911
18. Enia G, Sicuso C, Alati G, Zoccali C: Subjective global assessment of nutrition in dialysis patients. Nephrol Dial Transplant 1993; 8: 1094-1098
19. Davies SJ, Phillips L, Naish PF, Russell GI: Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17: 1085-1092
20. Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, Vanholder R, Meijers B, Meert N, Fassbender WJ, Floege J, Jahnen-Dechent W, Ketteler M: Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: A prospective study. Nephrol Dial Transplant 2010; 25: 2672-2679
21. Isakova T, Xie H, Barchi-Chung A, Vargas G, Sowden N, Houston J, Wahl P, Lundquist A, Epstein M, Smith K, Contreras G, Ortega L, Lenz O, Briones P, Egbert P, Ikizler TA, Jueppner H, Wolf M: Fibroblast growth factor- 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6: 2688- 2695
22. Guillemant J, Cabrol S, Allemandou A, Peres G, Guillemant S: Vitamin D-dependent seasonal variation of PTH in growing male adolescents. Bone 1995; 17: 513-516
23. Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, Massart C, Moe SM, Monge M, Souberbielle JC: Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: A cross-sectional study. Am J Kidney Dis 2008; 51: 987-995
24. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P: Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 2006; 70: 345-350
25. Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ: PTH - a particularly tricky hormone: Why measure it at all in kidney patients? Clin J Am Soc Nephrol 2013; 8: 299-312
26. Smith ER, Cai MM, McMahon LP, Holt SG: Biological variability of plasma intact and Cterminal FGF23 measurements. J Clin Endocrinol Metab 2012; 97: 3357-3365
27. Krall EA, Sahyoun N, Tannenbaum S, Dallal GE, Dawson-Hughes B: Effect of vitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women. N Engl J Med 1989; 321: 1777-1783
28. Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT: FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 2004; 89: 4489-4492
29. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y: FGF-23 in patients with endstage renal disease on hemodialysis. Kidney Int 2004; 65: 1943-1946
30. Bolland MJ, Grey AB, Ames RW, Mason BH, Horne AM, Gamble GD, Reid IR: The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr 2007; 86: 959-964
31. Rodriguez-Rodriguez E, Navia-Lomban B, Lopez-Sobaler AM, Ortega RM: Associations between abdominal fat and body mass index on vitamin D status in a group of Spanish schoolchildren. Eur J Clin Nutr 2010; 64: 461- 467
32. Gilsanz V, Kremer A, Mo AO, Wren TA, Kremer R: Vitamin D status and its relation to muscle mass and muscle fat in young women. J Clin Endocrinol Metab 2010; 95: 1595-1601
33. Grundberg E, Brandstrom H, Ribom EL, Ljunggren O, Mallmin H, Kindmark A: Genetic variation in the human vitamin D receptor is associated with muscle strength, fat mass and body weight in Swedish women. Eur J Endocrinol 2004; 150: 323-328
34. Cirillo M, Ciacci C, De Santo NG: Age, renal tubular phosphate reabsorption, and serum phosphate levels in adults. N Engl J Med 2008; 359: 864-866
35. Ix JH, De Boer IH, Peralta CA, Adeney KL, Duprez DA, Jenny NS, Siscovick DS, Kestenbaum BR: Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in mesa. Clin J Am Soc Nephrol 2009; 4: 609-615
36. De Boer IH, Rue TC, Kestenbaum B: Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2009; 53: 399-407
37. Mirza MA, Alsio J, Hammarstedt A, Erben RG, Michaelsson K, Tivesten A, Marsell R, Orwoll E, Karlsson MK, Ljunggren O, Mellstrom D, Lind L, Ohlsson C, Larsson TE: Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 2011; 31: 219- 227
38. Ashikaga E, Honda H, Suzuki H, Hosaka N, Hirai Y, Sanada D, Nakamura M, Nagai H, Matsumoto K, Kato N, Mukai M, Watanabe M, Takahashi K, Shishido K, Akizawa T: Impact of fibroblast growth factor-23 on lipids and atherosclerosis in hemodialysis patients. Ther Apher Dial 2010; 14: 315-322
39. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M: Fibroblast growth factor-23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
40. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I: Elevated fibroblast growth factor-23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966
41. Olauson H, Qureshi AR, Miyamoto T, Barany P, Heimburger O, Lindholm B, Stenvinkel P, Larsson TE: Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: Are gender and cardiovascular disease confounding the relationship? Nephrol Dial Transplant 2010; 25: 3033- 3038